Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113005 | 0.90 | KDM4E (0.63) | HTR1BHTR1DKDM4ERECQLL3MBTL1 | |
| SCHEMBL2468934 | 0.85 | HTR1B (0.67) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL13881609 | 0.85 | HTR1B (0.61) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL8339774 | 0.84 | MAPT (0.52) | KDM4ERECQLL3MBTL1MAPT | |
| Bromide SCHEMBL9463695 | 0.83 | HTR1B (0.64) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL2470398 | 0.81 | DRD2 (0.68) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL7767418 | 0.79 | HTR1B (0.64) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL21595673 | 0.79 | DRD2 (0.66) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL12939850 | 0.79 | HTR1B (0.64) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 | |
| SCHEMBL12153434 | 0.79 | HTR1B (0.64) | HTR1BHTR1DKDM4ECHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-7067655-B2 | preparation of furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl, phenyl, pyrrolyl or C4-C6 cycloalkenyl- substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosines prepared from 2-amino-4,6-dihydroxypyrimidine, POCl3 and dimethylformamide | SCHERING CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-6897216-B2 | Adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1283839-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050026932-A1 | Adenosine A2a receptor antagonists | SCHERING CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| US-6630475-B2 | 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease | SCHERING CORPORATION | 2003-10-07 | — | — | US | disclosed |
| EP-1283839-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026932-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | HTR1B 70/4885HTR1D 104/4885KDM4E 3303/4885 |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | HTR1B 62/4885HTR1D 81/4885KDM4E 4009/4885 |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | HTR1B 67/4885HTR1D 91/4885KDM4E 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.